68Ga-Somatostatin Analog PET-CT Linked to Reduced Costs Reduced costs versus 111In-octreotide scintigraphy for imaging neuroendocrine tumors
For imaging neuroendocrine tumors, 68Ga-somatostatin analog positron emission tomography-computed tomography (PET-CT) is associated with reduced costs compared with 111In-octreotide scintigraphy, according to a study published online July 17 in the Journal of Medical Imaging and Radiation Oncology. {read more here}
A significant portion of people with mild cognitive impairment or dementia who are taking medication for Alzheimer’s may not actually have the disease, according to interim results of a major study underway to see how PET scans could change the nature of Alzheimer’s diagnosis and treatment. {read more here}
Not only do [PET] scans pick up problems early, when drugs or lifestyle changes could make a difference, but they could also help reassure people who are suffering mild memory problems that they do not have the disease. {read more here}
To determine a baseline assessment, participants undergo a battery of cognitive and physical tests over two days at USC’s Health Science Campus that includes neuroimaging via MRI and PET scanning. {read more here}